August 13, 2014
1 min read

PAT Survey shows treat-and-extend holding steady as preferred strategy

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

SAN DIEGO — The same questions have yielded different answers over the years.

About 32% of the membership responded to the 2014 Preferences and Trends (PAT) Survey, Thomas Stone, MD, told colleagues at the annual meeting of the American Society of Retina Specialists here. Of the 75 questions included, some are asked from year to year, giving the opportunity to track trends, Stone said.

Thomas Stone

“In terms of treatment strategy, treat-and-extend became steadily more popular until 2013, and it remains the predominant treatment method for seeing and treating patients with macular degeneration,” Stone said.

Since the question was posed in 2007, the survey showed a fairly dramatic increase in the number of physicians choosing to treat bilateral, wet age-related macular degeneration at one visit rather than injecting only one eye per visit, according to Stone.

In 2005, observation was the main course of action in about 30% of cases of submacular hemorrhage due to AMD, he said.

“There really wasn’t much to offer; we really didn’t have anti-VEGF therapy on the scene at that point,” Stone said.

However, in 2014, anti-VEGF therapy predominates as treatment, according to Stone.

In 2010, primary management for macular edema with visual acuity of 20/25 and fluid seen on optical coherence tomography was likely to be laser.

“That number has decreased substantially over the last 4 years,” Stone said, attributing the trend to the availability of Lucentis (ranibizumab, Genentech) for diabetic macular edema.

Disclosure: Stone has no relevant financial disclosures.